Sernova Biotherapeutics Inc. (OTC: SEOVF) Awarded FDA Clearance for Cell Pouch Product

A number of companies are expected to come onto the radars of investors in a big way this morning, and in light of yesterday’s developments, Sernova Biotherapeutics Inc. (OTC: SEOVF) could be one of those. The regenerative medicine leader was in focus after it made an announcement about an FDA clearance for its Cell Pouch product.

IND Application Cleared

The company announced that its IND (Investigational New Drug) application to evaluate its Cell Pouch had been cleared by the United States Food and Drug Administration. In the evaluation in question, the product would be evaluated with auto-transplanted thyroid cells in patients going through thyroid surgery to treat nodular thyroid disease. In the news release, the company went on to add that hypothyroidism, caused by insufficient production of thyroid hormone, affected millions of people worldwide. Patients who may have had thyroid surgery are especially susceptible to the disease.

Further Information

The company stated in its news release that the clearance from the United States FDA was a demonstration of the sort of progress that Sernova Biotherapeutics had made in the development of the product. It remains to be seen how the company progresses the product over the coming months.

CEO Quote

“The FDA’s clearance of our IND application to investigate our Cell Pouch bio-hybrid organ in an additional indication is great progress,” said Jonathan Rigby, CEO of Sernova. “This further demonstrates that our technology has the potential to play an important role in advancing cell therapies that improve the quality of life for patients suffering from chronic illnesses.”